Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy

Clinical Pharmacokinetics

Volumn 44, Issue 5, 2005, Pages 517-523

  Ragueneau Majlessi, Isabelle ^a   Levy, Rene H ^a   Brodie, Martin ^b   Smith, David ^c   Shah, Jaymin ^d   Grundy, John S ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d GILEAD SCIENCES   (United States)

^e ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL; VALPROIC ACID; ZONISAMIDE;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; DRUG TOLERABILITY; EMOTIONAL DISORDER; EPILEPSY; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RASH; STEADY STATE; XEROSTOMIA;

ADULT; ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 19544385958     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544050-00005     Document Type: Article

References (18)

1. Seino M, Fujitani B. Zonisamide: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 885-91
2. Shah J, Shellenberger K, Canafax D. Zonisamide: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 873-9
3. Mather G, Carlson S, Trager W, et al. Prediction of zonisamide interactions based on metabolic isozymes [abstract]. Epilepsia 1997; 38 Suppl. 8: 108
4. Scheyer R. Valproic acid: drug interactions. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 801-7
5. Wagner ML, Graves NM, Leppik IE, et al. The effect of felbamate on valproic acid disposition. Clin Pharmacol Ther 1994; 56: 494-502
6. Yuen AW, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511-3
7. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: 554-63
8. Levy R, Shen D, Abbott F, et al. Valproic acid: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 780-800
9. Sadeque AJ, Fisher MB, Korzekwa KR, et al. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-enevalproic acid. J Pharmacol Exp Ther 1997; 283: 698-703
10. Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther 1999; 24: 347-55
11. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 2003; 65: 1441-9
12. Tasaki K, Minami T, Ieiri I, et al. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Brain Dev 1995; 17: 182-5
13. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67-73
14. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-63
15. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20: 593-7
16. Shinoda M, Akita M, Hasegawa M, et al. The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Biol Pharm Bull 1996; 19: 1090-2
17. Nakasa H, Nakamura H, Ono S, et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol 1998; 54: 177-83
18. Nakasa H, Komiya M, Ohmori S, et al. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 1993; 44: 216-21